CROSS-OVER ANALYSIS OF THE CONTROL OF RISK FACTORS AND ANTIAGGREGATION WITH POLIPILL (POLICROSS TRIAL)

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518705-18-00

Enrollment

Registered

2024-11-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degree of control coronary risk factors and platelet aggregation

Brief summary

Systolic blood pressure level. LDL cholesterol.

Detailed description

Systolic blood pressure level. LDL cholesterol.

Interventions

DRUGTrinomia 100 mg/20 mg/5 mg cápsulas duras.

DRUGTrinomia 100 mg/40 mg/5 mg cápsulas duras.

DRUGAdiro 100 mg comprimidos gastrorresistentes EFG

DRUGTrinomia 100 mg/20 mg/2

DRUG5 mg cápsulas duras.

DRUGCardyl 40 mg comprimidos recubiertos con película

DRUGAcovil 10 mg comprimidos

DRUGCardyl 20 mg comprimidos recubiertos con película

DRUGTrinomia 100 mg/20 mg/10 mg cápsulas duras.

DRUGTrinomia 100 mg/40 mg/2

DRUGTrinomia 100 mg/40 mg/10 mg cápsulas duras.

DRUGAcovil 5 mg comprimidos

DRUGAcovil 2

DRUG5 mg comprimidos

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure level. LDL cholesterol.	—

Secondary

Measure	Time frame
Systolic blood pressure level. LDL cholesterol.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026